BOSTON — From 2019 to 2023, insurance covered GLP-1 receptor agonist prescriptions at a Texas hospital for less than 70% of young people with type 2 diabetes and less than 40% of those with obesity.In addition, 44% of pediatric patients with obesity and 17% with type 2 diabetes prescribed liraglutide (Saxenda, Victoza; Novo Nordisk) discontinued the medication before reaching the approved